Weight Loss

3 articles

Slender Me Medical Semaglutide Review 2026: Is It the Right Weight Loss Choice for You?

This article reviews Slender Me Medical's semaglutide program, highlighting the benefits of medically-supervised weight loss over impersonal online services. It emphasizes the importance of comprehensive care, personalized dosing, and professional management of potential side effects.

Sponsored by Slender Me Medical·July 27, 2026

Pharmaceutical scientist analyzing molecular data, representing the complex balance between drug efficacy and patient tolerability in obesity treatment.

Computational Science & Software

Boehringer's obesity drug shows efficacy, faces tolerability challenge

In a pivotal Phase 3 obesity trial, 19% of patients on Boehringer Ingelheim and Zealand Pharma's experimental drug survodutide discontinued treatment due to severe gastrointestinal side effects, a rat

Yasmin Haddad·June 8, 2026

A scientist in a futuristic lab examining a holographic display of a triple hormone receptor drug, representing Pfizer's new obesity treatment.

Cosmos & Physics

Pfizer advances monthly obesity drug targeting triple hormone receptors

Pfizer is advancing a monthly weight-loss injection, danuglipron, having announced positive early-stage data.

Dr. Evelyn Reed·June 7, 2026